HIVNCT04504981
Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)
A study testing Y2Prevent in people with HIV and Drug Use, run by Children's Hospital Los Angeles at 1 site in United States.
Trial summary
The goal of this clinical trial is to pilot test a group level intervention, called Y2Prevent, which aims to decrease drug use and HIV/STI risk among Black/African American young men who have sex with men (AAYMSM). Read more about this study
- Who is it for?
- Ages 18 to 24 years, men onlyHealthy volunteers can take part
- What is being tested?
- Y2Prevent
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Jan 2020to 1 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 24 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18-24 years old;
- identify as a cisgender male;
- identify as Black/African American;
- identify as gay, bisexual, or some other same-sex identity, and/or report having had sex with a man;
- HIV-negative;
- not currently enrolled in an HIV prevention study;
Show all 9Show fewer
- living in the Los Angeles metro area;
- has access to a device (laptop, tablet or phone) with internet access in order to participate in virtual group sessions, complete online surveys, and receive payment via Venmo or Cash App; and
- has access to a telephone in order to be able to participate in and complete the qualitative exit interview, which will be conducted via telephone.
Who cannot join
- outside age 18-24 years old;
- identify as a transgender man or woman;
- identify as White/Caucasian, Latino/Hispanic, Asian/Pacific Islander, Native American, Indigenous, or any other ethnicity besides African American;
- identify as straight;
- HIV-positive;
- currently enrolled in an HIV prevention study;
Show all 9Show fewer
- currently living outside the Los Angeles metro area;
- does not have access to a device (laptop, tablet or phone) with internet access, which is necessary to participate in weekly group sessions, complete online surveys and receive payment for participation via Venmo or Cash App; and
- does not have access to a telephone, which is necessary to participate in the qualitative exit interview at the end of the seventh and final study session.
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Hospital Los Angeles
Los Angeles, California, 90027
About this study
Official title: HIV Prevention for High Risk African American Young Men
The goal of this clinical trial is to pilot test a group level intervention, called Y2Prevent, which aims to decrease drug use and HIV/STI risk among Black/African American young men who have sex with men (AAYMSM). The main question it aims to answer is:
- determine if Y2Prevent is possible to engage in easily and is accepted by the participants, for potential expansion to other cities.
Read more
Participants will engage in 7 weekly group sessions focused on helping AAYMSM identify life goals and safeguard their health to achieve those goals. This intervention will also include:
- HIV/STI testing and treatment referral
- drug screening and treatment referral
- positive youth development and future planning through a mentorship program
Read the detailed description
The overarching aim is to develop a culturally tailored and developmentally appropriate HIV prevention intervention for African American young men who have sex with men (AAYMSM), ages 18 to 24 years. No group is at greater risk for acquiring HIV than YMSM, especially those living in inner cities, with AAYMSM now accounting for the largest number of new HIV infections detected in cities each year. If these trends continue, it is estimated that as many as 1 in 2 AAYMSM will be diagnosed with HIV in their lifetime.
The investigators propose to further refine and pilot test an intervention, called Young Men's Adult Identity Mentoring (YM-AIM). Adapted from an existing CDC Diffusing Effective Behavioral Intervention (DEBI), YM-AIM is a theory-driven, group-level intervention designed to help AAYMSM develop a healthy vision for their future (or "possible future self") by defining a set of short- and long-term goals in the areas of education, health, family and intimate relationships. Through the facilitated activities, participants consider how their involvement in risky behaviors (e.g., illicit drug use, condomless sex, multiple sex partners) would interfere with achieving those goals. With funding from NIDA (R21 DA024588), the investigators developed YM-AIM in response to findings from our own research, as well as those reported in the literature, which demonstrate that experiences of minority stress (e.g., racism, homophobia) and exposure to violence and victimization (family, intimate partner, community) put AAYMSM at significantly greater risk for illicit drug use, HIV/STI sexual risk (condomless anal sex), and mental health problems (e.g., depression) as compared to Caucasian and Hispanic/Latino YMSM.
During our initial pilot, participants (n=36) were enormously enthusiastic about their participation in YM-AIM (all participants attended all six weekly sessions), they provided positive feedback about the various components, activities, and exercises, and they reported that YM-AIM should continue to be delivered using a group-based intervention because they enjoyed the support provided by other group members. Participants also reported they wanted (and needed) ongoing social support after completing the intervention, to help them achieve their short- and long-term goals and maintain positive changes in sexual risk behaviors. This feedback is consistent with the literature that suggests mentors are immensely beneficial, particularly for youth and young adults, because they can share their worldviews, experiences, knowledge, support and advice, as well as provide a positive influence. By introducing youth to new experiences and sharing positive values, mentors can help young people avoid negative behaviors and achieve success. Having a mentor has also been found to reduce youths' risk for delinquency, aggression and drug use and lead to increased academic satisfaction and performance. Based on this, the investigators propose to further strengthen and refine YM-AIM by adding a youth mentoring/support component, called Youth Initiated Mentoring (YIM). YIM uses a positive youth development framework to help young, low-income ethnic/racial minorities: a) build social capital to achieve immediate and long-term life goals, b) build social support networks, c) identify and engage natural mentors in their networks to address structural barriers encountered in their lives, and d) develop relationships with supportive adults.
YM-AIM was developed in 2011, before widespread availability of PrEP/PEP. The investigators are therefore also proposing to add three new components: 1) biomedical HIV prevention strategies (PrEP, PEP), 2) HIV/STI testing and treatment referral, and 3) drug screening and treatment referral. This new intervention, which is called Y2Prevent, will then be evaluated for its feasibility and acceptability. Intervention outcomes include drug use in past 30 days and 3 months, alcohol use, condomless sex, number of partners, condom use intention, condom use self-efficacy, HIV testing recency/frequency, and linkage to care. The specific aims are to:
SPECIFIC AIM 1: Conduct formative research to develop Y2Prevent and refine our assessment measures.
SPECIFIC AIM 2: Finalize Y2Prevent study protocols and consents and develop a manual of operations.
SPECIFIC AIM 3: Pilot and evaluate Y2Prevent to determine intervention feasibility and acceptability, and collect prelimiary efficacy data.
e propose to integrate YM-AIM and YIM into a single new intervention, called Y2Prevent. This intervention will then be implemented and evaluated for feasibility and acceptability, and manualized. Three phases of research are proposed. In Phase 1, the investigators will conduct formative research to integrate YM-AIM and YIM and refine our assessment battery (Aim 1). In Phase 2, the investigators will finalize the study protocols and consents and develop a manual of operations (Aim 2). In Phase 3, investigators will pilot test Y2Prevent with 30 participants. Assessment measures will also be pilot tested during three assessment sessions, at baseline (first study visit) and 3- and 6-month follow-up (after post-intervention test). Intervention outcomes include drug use in past 30 days and 3 months, alcohol use, condomless sex, number of partners, condom use intention, condom use self-efficacy, HIV testing recency/frequency, and linkage to care. Findings from this pilot research will inform selection of measures and outcomes for a future randomized clinical trial (RCT) and provide estimates of possible intervention effect sizes (group means, SDs) for trial planning. Process measures include data on sources of recruitment and recruitment rates, trial retention rates, and identification of barriers and facilitators to recruitment and retention.
WORKING GROUPS - PHASE 1:
During Phase 1, the investigators will convene two working groups of AAYMS to engage in a process of integrating the Young Men's Adult Identity Mentoring (YM-AIM) and Youth Initiated Mentoring (YIM). Each work group will include 8-10 young men. These men will be recruited from our existing HYM cohort.
Prior experience has taught us that creating groups with shared key characteristics (e.g. risk profile, sexual identity or age) is the most effective means of facilitating more in-depth discussions. Each group, consisting of 6-8 members, will be convened on a weekly basis and each meeting will focus on one specific topic (i.e.,common challenges that AAYMSM experience with HIV prevention; what AAYMSM want from a mentor) - there will be around 7 weekly lessons that participants will attend. During these meetings, participants will review each unit of the original YM-AIM and YIM curricula and discuss what components would be most relevant. Groups will be facilitated by the research assistant, and each week a volunteer from each group will be asked to serve as a co-facilitator in an effort to increase ownership for intervention adaptation and to assist in maintaining order within the group.
Guided discussions will focus on different aspects of the curricula such as: 1) common challenges that AAYMSM experience with HIV prevention; 2) what AAYMSM want from a mentor; 3) managing positive and negative influences in their lives; 4) challenges in accessing care; and 5) the role that intimate partners play in their lives. The investigators will brainstorm potential activities that can be integrated into our newly adapted Y2Prevent curriculum that focus on these areas (e.g., PrEP Myth or Truth game).
PILOT TEST - PHASE 3: In Phase 3, the investigators will pilot test Y2Prevent with three working groups of African American young men who have sex with men (AAYMSM) in Los Angeles. Each group will have up to 10 members (n=30). The intervention will be delivered to the three groups in a sequential order so that the experiences from the first group can be used to adapt and/or further refine the intervention before it is pilot tested with the second group. Feedback from the first group will be used to further adapt and refine the intervention. It will be pilot tested again with a second group of 10 participants. Y2Prevent will be further refined as needed, and it will then be pilot tested with a third and final group of up to ten participants. The investigators will continue to gather information, solicit input, and refine Y2Prevent until the investigators are satisfied that the intervention is truly relevant, acceptable, and appropriate for the target population. These group discussions will be audio-recorded and professionally transcribed for analysis. The focus groups are expected to last 1.5 - 2 hours each.
- Being tested
- Y2Prevent
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Y2PreventBehavioural
Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
| Study group | Role | What they receive |
|---|---|---|
| Y2Prevent Intervention | Other | Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans. Receives: Behavioral: Y2Prevent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sexual risk behaviors
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Measured: Baseline
Alcohol and illincit drug use
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Measured: Baseline; will asses past 30-day use; past 3 month
Sexual risk behaviors
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Measured: 3 months post intervention
Alcohol and illincit drug use
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Measured: 3 months post intervention
Sexual risk behaviors
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Measured: 6 months post intervention
Alcohol and illincit drug use
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Measured: 6 months post intervention
Illincit drug use
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
Measured: urine analysis for recent drug use (up to 1 week) at time of assessment (baseline)
Illincit drug use
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
Measured: urine analysis for recent drug use (up to 1 week) at time of assessment (3 months post intervention)
Illincit drug use
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
Measured: urine analysis for recent drug use (up to 1 week) at time of assessment (6 months post intervention)
Secondary outcomes (2)
PrEP Uptake
Measured with urine analysis
Measured: Current PrEP use at time of assessment (3 months post)
PrEP Uptake
Measured with urine analysis
Measured: Current PrEP use at time of assessment (6 months post)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2020
- Study start22 Jan 2020
- Primary completion22 Dec 2022
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by Children's Hospital Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- In Phase 3, we will pilot test Y2Prevent with three groups of African American young men who have sex with men (AAYMSM) in Los Angeles. Each group will have up to 10 members (n=30). The intervention will be delivered to the three groups in a sequential order so that the experiences from the first group can be used to adapt and/or further refine the intervention before it is pilot tested with the second group. Feedback from the first group will be used to further adapt and refine the intervention. It will be pilot tested again with a second group of 10 participants. Y2Prevent will be further refined as needed, and it will then be pilot tested with a third and final group of up to ten participants.
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Principal investigator, Michele D. Kipke, Children's Hospital Los Angeles
- Investigators
- Michele D Kipke, PhD, Principal investigator, Children's Hospital Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04504981
- Sponsor's protocol ID
- CHLA-19-00029
- Other IDs
- R34DA044106
- Status last verified
- Jul 2023
- First submitted
- 3 Aug 2020
- Last updated
- 18 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Researchers interested in the Y2Prevent data can request access to baseline and follow up survey data, specimen collection data and qualitative data from the intervention pilot groups in the form of written transcriptions. A publication plan and data use agreement would be reviewed and approved by the PI prior to sharing any data.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HIV Prevention for High Risk African American Young Men
- ClinicalTrials.gov ID
- NCT04504981
- Acronym / sponsor ID
- CHLA-19-00029
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Children's Hospital Los AngelesUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 22 Jan 2020 (actual)
- Primary completion
- 22 Dec 2022 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 7 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to pilot test a group level intervention, called Y2Prevent, which aims to decrease drug use and HIV/STI risk among Black/African American young men who have sex with men (AAYMSM). The main question it aims to answer is:
- determine if Y2Prevent is possible to engage in easily and is accepted by the participants, for potential expansion to other cities.
Participants will engage in 7 weekly group sessions focused on helping AAYMSM identify life goals and safeguard their health to achieve those goals. This intervention will also include:
- HIV/STI testing and treatment referral
- drug screening and treatment referral
- positive youth development and future planning through a mentorship program
Detailed description
The overarching aim is to develop a culturally tailored and developmentally appropriate HIV prevention intervention for African American young men who have sex with men (AAYMSM), ages 18 to 24 years. No group is at greater risk for acquiring HIV than YMSM, especially those living in inner cities, with AAYMSM now accounting for the largest number of new HIV infections detected in cities each year. If these trends continue, it is estimated that as many as 1 in 2 AAYMSM will be diagnosed with HIV in their lifetime.
The investigators propose to further refine and pilot test an intervention, called Young Men's Adult Identity Mentoring (YM-AIM). Adapted from an existing CDC Diffusing Effective Behavioral Intervention (DEBI), YM-AIM is a theory-driven, group-level intervention designed to help AAYMSM develop a healthy vision for their future (or "possible future self") by defining a set of short- and long-term goals in the areas of education, health, family and intimate relationships. Through the facilitated activities, participants consider how their involvement in risky behaviors (e.g., illicit drug use, condomless sex, multiple sex partners) would interfere with achieving those goals. With funding from NIDA (R21 DA024588), the investigators developed YM-AIM in response to findings from our own research, as well as those reported in the literature, which demonstrate that experiences of minority stress (e.g., racism, homophobia) and exposure to violence and victimization (family, intimate partner, community) put AAYMSM at significantly greater risk for illicit drug use, HIV/STI sexual risk (condomless anal sex), and mental health problems (e.g., depression) as compared to Caucasian and Hispanic/Latino YMSM.
During our initial pilot, participants (n=36) were enormously enthusiastic about their participation in YM-AIM (all participants attended all six weekly sessions), they provided positive feedback about the various components, activities, and exercises, and they reported that YM-AIM should continue to be delivered using a group-based intervention because they enjoyed the support provided by other group members. Participants also reported they wanted (and needed) ongoing social support after completing the intervention, to help them achieve their short- and long-term goals and maintain positive changes in sexual risk behaviors. This feedback is consistent with the literature that suggests mentors are immensely beneficial, particularly for youth and young adults, because they can share their worldviews, experiences, knowledge, support and advice, as well as provide a positive influence. By introducing youth to new experiences and sharing positive values, mentors can help young people avoid negative behaviors and achieve success. Having a mentor has also been found to reduce youths' risk for delinquency, aggression and drug use and lead to increased academic satisfaction and performance. Based on this, the investigators propose to further strengthen and refine YM-AIM by adding a youth mentoring/support component, called Youth Initiated Mentoring (YIM). YIM uses a positive youth development framework to help young, low-income ethnic/racial minorities: a) build social capital to achieve immediate and long-term life goals, b) build social support networks, c) identify and engage natural mentors in their networks to address structural barriers encountered in their lives, and d) develop relationships with supportive adults.
YM-AIM was developed in 2011, before widespread availability of PrEP/PEP. The investigators are therefore also proposing to add three new components: 1) biomedical HIV prevention strategies (PrEP, PEP), 2) HIV/STI testing and treatment referral, and 3) drug screening and treatment referral. This new intervention, which is called Y2Prevent, will then be evaluated for its feasibility and acceptability. Intervention outcomes include drug use in past 30 days and 3 months, alcohol use, condomless sex, number of partners, condom use intention, condom use self-efficacy, HIV testing recency/frequency, and linkage to care. The specific aims are to:
SPECIFIC AIM 1: Conduct formative research to develop Y2Prevent and refine our assessment measures.
SPECIFIC AIM 2: Finalize Y2Prevent study protocols and consents and develop a manual of operations.
SPECIFIC AIM 3: Pilot and evaluate Y2Prevent to determine intervention feasibility and acceptability, and collect prelimiary efficacy data.
e propose to integrate YM-AIM and YIM into a single new intervention, called Y2Prevent. This intervention will then be implemented and evaluated for feasibility and acceptability, and manualized. Three phases of research are proposed. In Phase 1, the investigators will conduct formative research to integrate YM-AIM and YIM and refine our assessment battery (Aim 1). In Phase 2, the investigators will finalize the study protocols and consents and develop a manual of operations (Aim 2). In Phase 3, investigators will pilot test Y2Prevent with 30 participants. Assessment measures will also be pilot tested during three assessment sessions, at baseline (first study visit) and 3- and 6-month follow-up (after post-intervention test). Intervention outcomes include drug use in past 30 days and 3 months, alcohol use, condomless sex, number of partners, condom use intention, condom use self-efficacy, HIV testing recency/frequency, and linkage to care. Findings from this pilot research will inform selection of measures and outcomes for a future randomized clinical trial (RCT) and provide estimates of possible intervention effect sizes (group means, SDs) for trial planning. Process measures include data on sources of recruitment and recruitment rates, trial retention rates, and identification of barriers and facilitators to recruitment and retention.
WORKING GROUPS - PHASE 1:
During Phase 1, the investigators will convene two working groups of AAYMS to engage in a process of integrating the Young Men's Adult Identity Mentoring (YM-AIM) and Youth Initiated Mentoring (YIM). Each work group will include 8-10 young men. These men will be recruited from our existing HYM cohort.
Prior experience has taught us that creating groups with shared key characteristics (e.g. risk profile, sexual identity or age) is the most effective means of facilitating more in-depth discussions. Each group, consisting of 6-8 members, will be convened on a weekly basis and each meeting will focus on one specific topic (i.e.,common challenges that AAYMSM experience with HIV prevention; what AAYMSM want from a mentor) - there will be around 7 weekly lessons that participants will attend. During these meetings, participants will review each unit of the original YM-AIM and YIM curricula and discuss what components would be most relevant. Groups will be facilitated by the research assistant, and each week a volunteer from each group will be asked to serve as a co-facilitator in an effort to increase ownership for intervention adaptation and to assist in maintaining order within the group.
Guided discussions will focus on different aspects of the curricula such as: 1) common challenges that AAYMSM experience with HIV prevention; 2) what AAYMSM want from a mentor; 3) managing positive and negative influences in their lives; 4) challenges in accessing care; and 5) the role that intimate partners play in their lives. The investigators will brainstorm potential activities that can be integrated into our newly adapted Y2Prevent curriculum that focus on these areas (e.g., PrEP Myth or Truth game).
PILOT TEST - PHASE 3: In Phase 3, the investigators will pilot test Y2Prevent with three working groups of African American young men who have sex with men (AAYMSM) in Los Angeles. Each group will have up to 10 members (n=30). The intervention will be delivered to the three groups in a sequential order so that the experiences from the first group can be used to adapt and/or further refine the intervention before it is pilot tested with the second group. Feedback from the first group will be used to further adapt and refine the intervention. It will be pilot tested again with a second group of 10 participants. Y2Prevent will be further refined as needed, and it will then be pilot tested with a third and final group of up to ten participants. The investigators will continue to gather information, solicit input, and refine Y2Prevent until the investigators are satisfied that the intervention is truly relevant, acceptable, and appropriate for the target population. These group discussions will be audio-recorded and professionally transcribed for analysis. The focus groups are expected to last 1.5 - 2 hours each.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- In Phase 3, we will pilot test Y2Prevent with three groups of African American young men who have sex with men (AAYMSM) in Los Angeles. Each group will have up to 10 members (n=30). The intervention will be delivered to the three groups in a sequential order so that the experiences from the first group can be used to adapt and/or further refine the intervention before it is pilot tested with the second group. Feedback from the first group will be used to further adapt and refine the intervention. It will be pilot tested again with a second group of 10 participants. Y2Prevent will be further refined as needed, and it will then be pilot tested with a third and final group of up to ten participants.
| Arm | Type | Receives |
|---|---|---|
| Y2Prevent Intervention | Other | Behavioral: Y2PreventY2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans. |
Who may qualify
- Ages
- 18 to 24 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- 18-24 years old;
- identify as a cisgender male;
- identify as Black/African American;
- identify as gay, bisexual, or some other same-sex identity, and/or report having had sex with a man;
- HIV-negative;
Key exclusion criteria (9 listed)
- outside age 18-24 years old;
- identify as a transgender man or woman;
- identify as White/Caucasian, Latino/Hispanic, Asian/Pacific Islander, Native American, Indigenous, or any other ethnicity besides African American;
- identify as straight;
- HIV-positive;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Y2PreventY2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals | Behavioural | Y2Prevent Intervention |
Primary outcome
Sexual risk behaviors
Time frame: Baseline
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Alcohol and illincit drug use
Time frame: Baseline; will asses past 30-day use; past 3 month
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Sexual risk behaviors
Time frame: 3 months post intervention
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Alcohol and illincit drug use
Time frame: 3 months post intervention
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Sexual risk behaviors
Time frame: 6 months post intervention
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Alcohol and illincit drug use
Time frame: 6 months post intervention
Frequency of acohol and illiict drug use including cocain, ecstasy, methamphetamines, psychedilic drugs (e.g., LSD, shrooms); heroin, opiates, prescription drugs without a prescription; marijuana
Illincit drug use
Time frame: urine analysis for recent drug use (up to 1 week) at time of assessment (baseline)
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
Illincit drug use
Time frame: urine analysis for recent drug use (up to 1 week) at time of assessment (3 months post intervention)
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
Illincit drug use
Time frame: urine analysis for recent drug use (up to 1 week) at time of assessment (6 months post intervention)
Presence of marijuana, methamphetamines, cocaine, heroin, opiates, barbituates, benzodiazepines, ecstasty, GHB, PCP
2 secondary outcomes
PrEP Uptake
Time frame: Current PrEP use at time of assessment (3 months post)
PrEP Uptake
Time frame: Current PrEP use at time of assessment (6 months post)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2023.
- Individual participant dataSharing planned: Yes. Researchers interested in the Y2Prevent data can request access to baseline and follow up survey data, specimen collection data and qualitative data from the intervention pilot groups in the form of written transcriptions. A publication plan and data use agreement would be reviewed and approved by the PI prior to sharing any data.
Related trials for HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michele D Kipke, PhD principal investigator
Children's Hospital Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Y2Prevent in people with HIV and Drug Use, run by Children's Hospital Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sexual risk behaviors (time frame: Baseline). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2023.